Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer

Chiara Della Pepa, Susana Banerjee

Research output: Contribution to journalArticlepeer-review


Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.

Original languageEnglish
Pages (from-to)1025-1031
Number of pages7
JournalOncoTargets and Therapy
Publication statusPublished - Jun 19 2014


  • Antiangiogenic
  • Ovarian
  • Recurrent

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer'. Together they form a unique fingerprint.

Cite this